Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
Authors:
- Milton PackerMPMilton Packer
- for the EMPEROR-Preserved Trial Study GroupFGfor the EMPEROR-Preserved Trial Study Group
Open Access
- 30 August 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 23 (10) , 1798-1799
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialCirculation, 2021
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine, 2021
- Empagliflozin and Major Renal Outcomes in Heart FailureNew England Journal of Medicine, 2021
- SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysisHeart Failure Reviews, 2021
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection FractionCirculation, 2021
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsThe Lancet, 2020
- Redefining Heart Failure With a Reduced Ejection FractionJAMA, 2019